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Patients with inherited anemia and hemoglobinopathies (such as sick-le cell disease and β-thalassemia) are treated with red blood cell(RBC) transfusions to alleviate their symptoms. Some of these
patients may have rare blood group types or go on to develop alloimmune
reactions, which can make it difficult to source compatible blood in the
donor population. Laboratory-grown RBC represent a particularly attrac-
tive alternative which could satisfy an unmet clinical need. The challenge,
however, is to produce - from a limited number of stem cells - the 2x1012
RBC required for a standard adult therapeutic dose. Encouraging progress
has been made in RBC production from adult stem cells under good man-
ufacturing practice. In 2011, the Douay group conducted a successful
proof-of-principle mini-transfusion of autologous manufactured RBC in a
single volunteer. In the UK, a trial is planned to assess whether manufac-
tured RBC are equivalent to RBC produced naturally in donors, by testing
an allogeneic mini-dose of laboratory-grown manufactured RBC in multi-
ple volunteers. This review discusses recent progress in the erythroid cul-
ture field as well as opportunities for further scaling up of manufactured
RBC production for transfusion practice.
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Introduction
Red blood cell (RBC) transfusions are the mainstay treatment for anemic patients
and are given routinely in hospitals around the world. Depending on the clinical
presentation, blood transfusions are likely to be administered to improve the
patients’ quality of life and are administered either intermittently when needed, or
for extended periods, as in the case of 50-90% of patients suffering from myelodys-
plastic syndromes and for transfusion-dependent patients with inherited anemia
and hemoglobinopathies (such as sickle cell disease and β-thalassemia). Chronic
RBC transfusions introduce secondary complications which contribute to morbid-
ity, due mainly to transfusion-induced iron overload and erythrocyte alloimmu-
nization.1,2 It is particularly challenging for blood services to source RBC compatible
for multiply alloimmunized patients with chronic transfusion-dependent anemia or
rare blood types.3,4
Breakthroughs in the field of erythropoiesis research have led to the development
of reproducible protocols that can yield large numbers of cultured human reticulo-
cytes, often referred to as laboratory-grown or cultured red blood cells (cRBC). In
addition to being an excellent model system for exploring human erythropoiesis in
health and disease, this work has laid the foundations for the interest in producing
human cRBC for transfusion purposes or as a vehicle for red cell-based therapeu-
tics. The production of cRBC from stem cells or other cellular sources (see below)
may one day fill the unmet clinical need for transfusion-dependent patients, but
only if the challenge of growing enough clinical grade RBC can be met. 
The term “manufactured RBC” (mRBC) refers to clinical grade cRBC grown
under good manufacturing practises (GMP). Both cRBC and mRBC are in fact nas-
cent RBC, known as reticulocytes5-7 and they are referred to only as mRBC within
this manuscript from now on to avoid confusion. One added benefit of mRBC,
compared to standard donor-derived RBC, is that they are a homogeneous popula-
tion of immature RBC that should last the normal 120-day lifetime in the circula-
tion. This regenerative medicine product is anticipated to reduce transfusion fre-
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quency and the associated iron overload.6 Support for this
idea comes from studies showing that transfusion of
young RBC (also called neocytes) is beneficial to patients
with inherited anemias, reducing iron overload and
increasing the interval between transfusions.8-12
mRBC have been tested in immunocompromised mice
models5,6,13 and non-human primates.13 Importantly, a
proof-of-principle mini-transfusion of autologous mRBC
has been conducted in a single volunteer, illustrating that
mRBC can survive in the circulation and are safe for use in
humans.5 The benefit of mRBC in allogeneic transfusions
across multiple recipients still needs to be demonstrated
before moving to patients. The commercial company
Rubius Therapeutics has a business model built around
producing novel mRBC for therapeutics. To date, Rubius
has conducted one injection of mRBC engineered for
treatment of phenylketonuria in a single patient (Rubius
press release 12th March 202014), but no further specific
information was released. In the UK, the National Health
Service Blood and Transplant (England’s Blood Service) is
intending to conduct a single-center, randomized, allo-
geneic, controlled, phase I, cross-over trial denominated
RESTORE (Recovery and Survival of Stem Cell Originated
Red Cells (ISRCTN:42886452 and EudraCT: 2017-002178-
38). This healthy volunteer trial has faced significant
delays, most recently due to the COVID-19 pandemic but
will, it is hoped, be carried out in the near future to assess
the recovery and survival of a mini-dose of mRBC derived
from CD34+ cells isolated from adult blood donors versus
the standard RBC from the same donor.
Laboratory-grown RBC offer the greatest potential in
terms of sourcing rare blood groups for sickle cell and tha-
lassemia patients with alloimmunity. It must be acknowl-
edged however, that these patients also present the great-
est challenge in terms of requirements for blood. Adult
patients require multiple units of blood per month.15
Realistically, the first therapeutic use of mRBC is likely to
take place in a pediatric setting or for red cell-based thera-
peutics, such as enzyme replacement therapies, as both
these applications require smaller numbers of mRBC.
There is also a need to determine the number of mRBC
that represents a therapeutic dose. For adult patients, one
unit of standard RBC is estimated to consist of approxi-
mately 2x1012 RBC which raises the hemoglobin of an
average adult by 1 g/dL. For pediatric patients, doses are
more variable as they depend on the weight of the patient
but are lower than an adult dose. It should be noted that a
proportion (5-10%) of standard RBC are lost within the
first 24 hours after transfusion16 and this increases to 25%
or more with blood storage time. Therefore, the actual
number of RBC required to treat anemia is likely to be
lower if the majority of the cells are nascent. 
Many excellent reviews have been written on mRBC
and the prospect of using mRBC for transfusion.17-25 We
therefore offer below a concise overview of the progress
to date, highlighting the relevant issues and opportunities
for optimizing and increasing the mRBC yield to an adult
therapeutic dose.
Overview of the erythroid culture process
The recapitulation of erythropoiesis using primary
hematopoietic stem and progenitor cells (HSPC) ex vivo
requires specific combinations of cytokines and growth
factors in order to first expand the HSPC, and then to
direct lineage specification to ensure full differentiation to
the reticulocyte stage (see Figure 1). Over the last 20 years,
multiple laboratories have developed two-dimensional
liquid culture systems that reproduce the process and
stages of human erythropoiesis to generate reticulocytes.
These include two to four stages, each characterized by
the inclusion or omission of specific growth factors (Table
1). The general consensus is for the inclusion of a primary
stage favoring HSPC expansion with interleukin-3 and
stem cell factor, a secondary erythroblast expansion stage
including stem cell factor and erythropoietin, followed by
a terminal differentiation stage with erythropoietin.
Notably, holotransferrin is included throughout the cul-
ture period. Some laboratories further modify the initial-
stage culture media by including, for example, throm-
bopoietin and fms-like tyrosine kinase 3 (Flt-3) to enhance
stem cell proliferation13 and may also include glucocorti-
coids to increase expansion prior to differentiation.26 The
more recent culture protocols listed in Table 1 have been
undertaken at considerably larger scale (i.e., at least 1 L),
with some reports of successful generation of large num-
bers of reticulocytes. The challenge for the field is to
increase the production even further to generate the
equivalent of a therapeutically useful adult dose. 
Starting material
The studies reporting the highest yields all use HSPC
specifically isolated from cord blood,13,27 mobilized5 or
standard peripheral blood6,28 (Table 1). Another option is to
use the whole peripheral blood mononuclear cell
(PBMNC) component for production of mRBC, thereby
omitting the expensive step of CD34+ isolation.7,29 As well
as reducing costs, the use of PBMNC as the starting mate-
rial under the correct culture conditions can contribute
towards increasing the yield of mRBC. Indeed, PBMNC
include all cells with erythroid lineage potential, some of
which are CD34- that can enhance culture yield.29 PBMNC
also include CD14+ cells that might act as helper/feeder
cells that can limit the cell death of erythroid progenitors
during the first few days of culture when volumes are still
small and cells are kept in static tissue culture flasks or
dishes.30,31
We highlight that there are other sources that are gain-
ing traction, including immortalized pluripotent stem cells
and immortalized cell lines,32,33 which can be used to dif-
ferentiate to reticulocytes, but we will not discuss these
here because these have not yet been grown at scale.
These sustainable cellular sources have great potential for
continual blood production once the technical challenges
of growing them have been circumvented and are likely to
comprise a second wave of blood products after stem cell-
derived mRBC.
Natural donor variation and yields
The genetic makeup of the donor-derived cellular start-
ing material has long been recognized to have an impact
on yield, which is problematic when trying to consistently
produce a high number of mRBC using random donors.34
This variation could be due to the number of HSPC pres-
ent per volume of blood, which is highly variable between
S. Pellegrin et al.
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donors, or down to subtle variations in genetic factors that
influence how HSPC and erythroid progenitors prolifer-
ate, enucleate and/or respond to culture media composi-
tion. More work is therefore needed to explain the differ-
ences in yields observed between donors under standard-
ized and reproducible culture conditions. The payoff from
this painstaking work would be the identification of
potential genetic variations that could be pre-screened for
or utilized by genetically engineering alterations the start-
ing material to benefit production. 
Genome-wide association studies as well as identifica-
tion of rare phenotypes linked to specific RBC traits might
help to identify genetic variants suitable for reliably pro-
ducing large numbers of mRBC. An example of such an
approach was carried out by Sankaran’s group.35
LNK/SH2B3 is an adaptor protein that negatively regulates
hematopoietic cytokine signaling. Rare lost-of-function
SH2B3 alleles have been associated with JAK2-mutation-
negative erythrocytosis36,37 and a hypomorphic allele of
SH2B3 (single nucleotide polymorphism rs3184504) was
found to be significantly associated with high hemoglobin
levels, packed cell volume and RBC count in vivo.38 Using
shRNA knockdown in adult, mobilized, peripheral blood
and cord blood CD34+ cells, Giani et al.35 suppressed the
expression of the LNK/SH2B3 protein and reported a 2- to
7-fold increase in yield of enucleated RBC in shRNA-treat-
ed cells compared to cells transduced with a control
shRNA. More recently, a study of rare MAM-negative
individuals by Thornton and colleagues39 showed that
peripheral blood CD34+ cells from two MAM-negative
individuals had a proliferation advantage in ex-vivo ery-
throid cultures, resulting in an average 5-fold increase in
cell number compared to four age- and gender-matched
MAM-positive controls. Whether the same observations
concerning loss-of-function SH2B3 and MAM-negative
cells hold true for large-scale cultures and across multiple
donors still needs to be determined.
Beyond yield, the choice of donor can also affect the
quality of the final mRBC product due to the donor’s own
RBC intrinsic characteristics – not just in terms of blood
group which can be selected for, but also in terms of stor-
age characteristics or even longevity in circulation once
transfused. The planned RESTORE clinical trial may pro-
vide data on this as the survival time of transfused stem
cell-derived mRBC in the circulation of the recipient will
be directly compared to the survival time in circulation of
the same donor’s standard RBC.
Genetic manipulation and small molecules
A key challenge for the field is to prevent the attrition of
the self-renewal capacity of HSPC and to maintain the
expansion capacity of erythroid progenitors (burst-form-
ing and colony-forming units-erythroid) for a longer peri-
od before terminal erythroid differentiation occurs. One
way to do this is through the use of glucocorticoids (see
below) which can potentially improve the asynchronicity
of enucleation in cultures, and may then improve reticulo-
cyte stability and filtration efficiency. Another way is to
Figure 1. Overview of the erythroid culture process. Ex vivo culture systems require the isolation of peripheral blood mononuclear cells (PBMNC) or magnetic sorting
of the CD34+ cells as starting material. Culture systems then employ either flasks, spinner flasks or a bioreactor system depending on scale. The volume of the culture
will increase dramatically as the cells expand and differentiate through days 7-14. Upon generation of a mixed population of reticulocytes, nucleated cells and pyreno-
cytes at day 21, cells then require filtration using either a syringe (small scale) or multiple leukocyte filters (large scale) depending on volume to give a pure reticulo-
cyte population. Diagram made using biorender.com.
use culture manipulation to try and maintain stemness
and proliferation potential. For example, there are small
molecule inhibitors that are reported to enhance cord
blood HSPC self-renewal, such as UM17140 and the aryl
hydrocarbon receptor agonist SR-1.41 There are also fac-
tors such as angiopoietin-like 5 and IGBFP242 and notch
ligand.43 Although there is evidence that these small mole-
cules or factors enhance HSPC expansion, there are no
data yet to suggest that they can enhance the yield of
reticulocytes when cultured on a large scale.
Perhaps the most exciting advancement in erythroid
progenitor manipulation is the recently reported overex-
pression of BMI1 in human HSPC, which gave a 1012 fold
increase of erythroblasts.44 Not only does the extensive
expansion give the potential for higher yields (assuming
the cells do not differentiate spontaneously when grown
in large volumes), it also confers the opportunity for fur-
ther genetic manipulation due to the extended time
frame. Genetic manipulation in the form of YTHDF2
knockdown also generated a reported 14.3-fold increase
in CD34+ frequency in the culture conditions used by a
separate group of researchers.45 Alternatively, better bio-
mimicry of the stem cell niche to recapitulate conditions
ex vivo has the potential to maintain HSPC stemness for
longer periods and therefore increase yield; however,
these technologies still require further development.46-52 It
will be very interesting to see if applications of these
innovations can translate into higher yields for large-
scale mRBC production.
Media composition and optimization 
As well as exploiting cell-intrinsic properties, the base
medium composition could be further developed and sup-
plemented. Erythroid progenitors are generally cultured in
Iscove modified Dulbecco medium (IMDM) and laborato-
ries maintain consistency with suppliers whenever possi-
ble. There are many different IMDM commercially avail-
able, some better than others in terms of supporting the
proliferation and enucleation of erythroid progenitors.
Studies are needed to determine exactly what nutrients
are required to support the highest proliferation rates of
HSPC and erythroid progenitors in culture, particularly
important when culturing at high cell densities.
Interestingly Heshusius et al. supplemented their IMDM
with nucleosides and a range of trace elements to make a
more defined GMP-compliant medium.7 Zhang and col-
leagues13 added folic acid and selenium to their large-scale
cultures of human cord blood CD34+ cells. An experimen-
tal approach, using parallel stirred tank micro-bioreactors,
is needed to identify the definitive media and supple-
ments to use for erythroid culture.  
The lipid sources added to base media by different lab-
oratories also vary significantly, with some groups favor-
ing different amounts of plasma, serum (human or
bovine) or serum-free conditions supplemented with ani-
mal, human or plant-derived lipid-rich reagents. For com-
pliance with GMP, animal sources must eventually be
substituted, which can have an impact on yields. In their
recent report Heshuvius et al. also highlighted the impor-
tance of albumin purity for proliferation.7 Interestingly,
Wilkinson et al.53 showed that 0.1% human serum albu-
min can be replaced by 0.1% polyvinyl alcohol for cul-
tures of human umbilical cord blood-derived CD34+ cells
but as yet this observation has not been tested on a large
scale. 
Glucocorticoids
The importance of glucocorticoids in promoting stress
erythropoiesis was originally discovered in avian and
mice studies54,55 and glucocorticoids have been used to
S. Pellegrin et al.
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Table 1. Summary of recently published, large-scale erythroid culture systems, with expansion and enucleation rates where provided as well as bioreactor
and GMP/non-GMP media constituents where applicable. Exhaustive reviews of small-scale erythroid cultures can be found elsewhere.20,22,25
Source and culture period        General protocol            Expansion               Enucleation rate                            Key points                                   Reference
Cord blood,                                            Two-stage                         2.3x108                                                     >90%                  First demonstration of bioreactor use;        Timmins et al., 2011 
33 days                                                                                        by extrapolation                                                    1 L cultures in wave-type bioreactor; 
                                                                                                                                                                                                       non-GMP (use of BSA)                                         
Peripheral blood                                 Three-stage                  6.15x104 fold                            68%                        1 culture of 2.5 mL packed filtered          Giarratana et al., 2011
CD34+ cells                                                                                  Large cultures                                                             mRBC under GMP conditions
                                                                                                         (actual yield)                                                              autologous human transfusion 
Peripheral blood                                 Three-stage                     >104 fold                             55-95%                           5 mL packed filtered mRBC,                  Griffiths et al., 2012
CD34+ cells,                                                                                Large cultures                                                         constant batch feeding in spinner
20 days                                                                                           (actual yield)                                                               flasks (no medium changes); 
                                                                                                                                                                                                                    non GMP 
Peripheral blood and                         Three-stage                     >105 fold                               63%                             Large scale cultures (~25 L)                   Kupzig et al., 2017 
cord blood CD34+ cells                                                            Large cultures                                                         10 mL packed filtered mRBC using 
20 days                                                                                           (actual yield)                                               constant batch feeding in spinner flasks under 
                                                                                                                                                                                                             GMP conditions
Cord blood                                             Four-stage                    2.9x105 fold                                                    Large scale culture in rotating wall vessels;      Zhang et al., 2017 
CD34+ cells                                                                                  Large cultures                                                                non-GMP (use of 15% FBS 
                                                                                                         (actual yield)                                                                             in steps 2 & 3)
Peripheral blood MNC                       Three-stage                      107 fold                               > 90%                                     G-Rex bioreactor                          Heshusius et al., 2019 
(no CD34+ cell isolation)                                                       by extrapolation                                                     GMP compliant: serum-free and plant
21 to 37 days                                                                                                                                                                        derived lipids for expansion; 
(due to expansion stage)                                                                                                                                          5% human plasma for differentiation                            
GMP: Good Manufacturing Practice; BSA: bovine serum albumin, mRBC: manufactured red blood cells, FBS: fetal bovine serum; MNC: mononuclear cells.
increase the yield of human mRBC.26,29,56,57 Three of the
larger-scale erythroid culture protocols reported to date
incorporate glucocorticoids, using either dexamethasone
in serum-free conditions7 or hydrocortisone in the pres-
ence of 5% plasma5 or in serum-free conditions.27
Recent studies have highlighted both the importance
of lipid metabolism during terminal erythroid differenti-
ation58 and the fact that exposure to glucocorticoids can
affect the lipid metabolism in cultured erythroid cells.59,60
For erythroid cells cultured in the presence of hydrocor-
tisone, the defect in lipid metabolism and resulting
fragility of mRBC can be counteracted by supplementing
the medium with cholesterol-rich lipids.60 Interestingly
though, addition of cholesterol-rich lipids slightly accel-
erated differentiation60 and Heshuvius et al. reported that
the addition of plasma caused premature differentiation
in the presence of dexamethasone.7 The interplay
between glucocorticoid exposure time and lipid metabo-
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Table 2. Highlighted strategies to improve current culture systems for manufactured red blood cells.
Improving yield & quality of mRBC
Starting material                                                • selection of donors with genetic markers linked to specific RBC traits (high hemoglobin, packed 
                                                                                   cell volume or RBC count) 
                                                                                   • selection of donors with consistently high HSPC counts
                                                                                   • use of whole mononuclear cell population (PBMNC) not just CD34+ cells
                                                                                   • genetic manipulation of starting material to enhance proliferation and compatibility
Media composition and supplements         • slow down attrition of HSPC self-renewal capacity
                                                                                   • maximize expansion of erythroid progenitors (CFU-E)
                                                                                   • maximize enucleation and maintain nascent reticulocyte viability
Filtration                                                                • novel filtration technology to minimize loss of mRBC
                                                                                   • maturation of mRBC to erythrocytes will enhance filtration efficiency
Storage                                                                   • optimal reticulocyte storage conditions to minimize loss of filtered mRBC until transfusion
                                                                                   • maturation of mRBC to erythrocytes to enhance storage times
GMP-compliance and reproducibility
Starting material                                                • minimize stem cell donor variability and cell loss during isolation
Media composition and supplements         • use defined reagents of known reliability and controlled provenance 
                                                                                   • multiple suppliers identified for key reagents
                                                                                   • supplier surveys and site visits
Bioreactors and filtration                                • closed systems
                                                                                   • scalable GMP-compliant bioreactors with ease of use 
                                                                                   • close monitoring of the culture growth
                                                                                   • GMP-compliant filtration process
Other considerations                                        • define release criteria of product and storage times
                                                                                   • identification of optimum therapeutic dose of mRBC
Cost reduction
Starting material                                                • use of PBMNC to circumvent expensive CD34+ cell isolation
Media composition and supplements         • defined in-house media constituents 
                                                                                   • in-house growth factors
                                                                                   • replace or reduce the most expensive constituents (e.g. holotransferrin)
                                                                                   • develop protocols/bioreactors that use less medium overall without affecting the yield and quality
                                                                                   of mRBC obtained
                                                                                   • enhance media to enable increases in cell density
Bioreactors and filtration                           • fully automated culture processes
                                                                                   • automated filtration
                                                                                   • minimal footprint and labor requirement
RBC: red blood cells; mRBC: manufactured RBC; HSPC: hematopoietic stem and progenitor cells; PBMNC: peripheral blood mononuclear cells; CFU-E: colony-forming unit –
erythroid; GMP: Good Manufacturing Practice.
lism needs further investigation to maximize yield with-
out compromising mRBC quality.
Holotransferrin
The majority of current protocols use between 0.33 and
0.7 mg/mL holotransferrin isolated from human plasma,5-7
which represents the highest costing individual culture
reagent. Holotransferrin is the natural carrier used to deliv-
er iron to the developing erythroid cell by binding to
CD71 and being internalized. It is then recycled by the cell
and released back into the medium in its apo-form. A
cheaper, plant-derived recombinant holotransferrin, opti-
ferrin, is available but this is still expensive. Theoretically,
the transferrin concentration could be reduced in culture
media as long as iron is also supplemented to bind apo-
transferrin, without causing cell toxicity or increasing the
likelihood of bacterial growth. For example, Timmins and
colleagues used 0.12 mg/mL holotransferrin in combina-
tion with 900 ng/mL ferrous sulfate and 90 ng/mL ferric
nitrate.27 Olivier et al. used holotransferrin at a concentra-
tion of 0.05 mg/mL and 3 mM FeIII-EDTA in small scale
immortalized pluripotent stem cell cultures, reportedly
without affecting the yield of reticulocytes, but the poten-
tial impact on mean cell hemoglobin concentrations and
viability during storage of the mRBC produced was not
measured.61 Other iron supplements that could be tested
include reagents that would deliver iron to erythroid cells
in a CD71-independent manner. These include the small
lipophilic molecule hinokitiol that can carry iron across
the cell membrane into erythroid cells62,63 or alternatively,
ferric carboxymaltose and iron sucrose, both already pre-
scribed to patients suffering from iron deficiency.64
Bioreactors and growing erythroid cells 
at larger scale
The majority of erythroid cultures described in the liter-
ature are small and rely on the use of static tissue plastic
flasks. For the reported larger scale cultures, a variety of
culture vessels have been utilized. The original 2.5 mL
packed mRBC produced under GMP conditions and tested
in a single volunteer were cultured in static plastic flasks.5
Spinner flasks (of 1.5 L and 3 L volumes) have since been
used successfully from day 7 onwards for constantly
batch-fed cultures reaching a volume of ~28 L to produce
10 mL of packed filtered reticulocytes.6 Zhang et al. used
rotating wall vessels to grow 2x108 cells from cord blood
CD34+.13 Most recently, Heshusius and colleagues used a 1
L gas-permeable, rapid expansion bioreactor (G-Rex;
Wilsonwolf) which, as well as facilitating partial media
replenishment, allowed 90% of the expansion medium to
be removed and replaced by differentiation medium.
Although the expansion was 10-fold lower in the G-Rex
compared to static dishes, the enucleation rate was similar
and by extrapolation the authors predicted that ~4.5 mL
mRBC could be produced using this bioreactor.7 The cell
numbers from these studies are encouraging but are still a
long way from the prediction by Timmins et al.,27 who
suggested it may be possible to produce 500 units from a
single cord blood donation.
There are still many types of bioreactors to choose from
and explore further for erythroid culture including: (i) con-
tinuous stirred tank bioreactors or spinner flasks which
contain internal impellers; (ii) fluidized bed bioreactors in
which cells are kept in suspension by the culture medium
moving upwards; (iii) rocking heated platforms (wave-like
bioreactors) onto which large disposable bags are
attached; (iv) rotating wall vessel bioreactors also known
as roller bottles and finally, (v) multi-layered static flasks.
Whatever becomes the bioreactor of choice for erythroid
cell culture, it will need to facilitate higher density culture,
be scalable and incorporate automation. In the long term,
this will make erythroid culture more cost-effective by: (i)
reducing labor costs - cells would be cultured in a single
container making the cultures easier to feed and less labor-
intensive, with the possibility of automated, remote feed-
ing of media and/or specific depleted nutrients; (ii) reduc-
ing the footprint and space required for each batch pro-
duction; (iii) easing scale up; and (iv) minimizing human
error and batch-to-batch variation by carefully controlling
different parameters (such as pH, agitation and oxygena-
tion) for optimal culture conditions. One can eventually
then imagine rooms filled with bioreactors manufacturing
mRBC continuously at scale for clinical use.
The challenge for producing mRBC in any of the above
types of bioreactors type lies in the variety of culture con-
ditions required during this 3-week process. All cultures
are initiated from a small number of HSPC or approxi-
mately 100x106 PBMNC, seeded in a small volume of
medium. The erythroid cells then proliferate reaching a
fold expansion of >105 and requiring low cell densities for
optimum growth (2-8x105 cells/mL) or medium replenish-
ment (constant versus repeated batch feeding).
Orthochromatic erythroblasts then enucleate and are rela-
tively fragile during this process. Moreover, erythroid cul-
tures are inherently asynchronous, a proportion of cells
start enucleating while others are still proliferating; this is
noticeable in the last week of culture. To maximize yield,
culture conditions have to support cells at different stages
of terminal differentiation and nascent reticulocytes must
remain viable until the highest percentage enucleation is
reached. A manufacturing process that uses a bioreactor
efficiently, minimizing the transitions between different
types of culture vessels during the 21 days of culture, pro-
ducing a high yield of reticulocytes and automating feed-
ing, still needs to be identified.
Once the final product is made (i.e., mRBC have been
filtered and stored), new cultures have to be reinitiated
using new donor-derived HSPC. This is where immortal-
ized pluripotent stem cells or an immortalized cell line
that enucleates efficiently would be a game-changer as
stocks of the same cell phenotype could be maintained.
Reticulocyte filtration and storage
At the end of the procedure, large-scale erythroid cul-
tures need to be volume reduced and filtered to separate
the mRBC from the nucleated cells and expelled nuclei
(also known as pyrenocytes). Currently, the filters used
are dead-end leukoreduction filters routinely used by
blood banks. These have been designed to filter whole
blood, which typically consists of ~ 5x109 RBC and only
~5x106 nucleated cells per milliliter of blood. In compari-
son, the percentage enucleation for mRBC cultures is
approximately 80% and the medium contains pyreno-
cytes as well as free DNA released by disintegrated nuclei.
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It is notable that very few studies on mRBC yield test the
filterability of their final product or report the yield after
filtration. This is a key parameter as the mRBC must be
purified before clinical use and this process currently alters
the yield by 30-50%. Strategies and more research are
needed to improve reticulocyte recovery after filtration,
which will lead to a dramatic increase in yield. There are
open-ended filter technologies, such as tangential flow fil-
tration systems or acoustic resonance cell filtration,65
which could potentially be used but are as yet untested.
More experimental approaches include lab-on-a-chip
microfluidic label-free reticulocyte-sorting methods.66 All
these possibilities need testing and optimizing on a large
culture scale which is expensive, therefore, highlighting
filtration as a key area of research calling for innovation as
well as commercial investment and collaboration.
Once filtered, the mRBC need to be stored whilst qual-
ity control tests are carried out and until they can be trans-
fused into a patient. As reticulocytes, mRBC are more
fragile than RBC and more optimal storage conditions
need to be developed. An alternative approach is to pro-
mote maturation of cultured reticulocytes into bona fide
erythrocytes, which is another area of active research.
Compliance with Good Manufacturing Practises
and quality control
Finally, it should be remembered that the challenge for
mRBC production is not only to deliver a manufacturing
process that can produce enough mRBC at scale but to
develop a process that is GMP-compliant. Often GMP
compliance includes the use of clean rooms, highly trained
staff specialized in GMP, using closed processes to mini-
mize any risk of infection, robust batch manufacturing
protocols, as well as specific manufacturing processing
and quality release criteria which are not required in stan-
dard R&D laboratories. The challenges of GMP compli-
ance on large-scale erythroid cultures for a transfusion
product may have an impact on yield, add pressure to cul-
ture times and increase costs, so will need to be consid-
ered and planned for from the outset. 
Summary
Technologies to revolutionize transfusion options for
patients with anemia, in particular for those receiving regu-
lar life-long transfusions, are much needed. There is great
potential for laboratory-grown mRBC to be used in transfu-
sion practice once production is mastered at scale. In the
meantime, these culture systems at smaller scale have
proven to be brilliant tools for understanding human ery-
thropoiesis and optimizing culture methodology. The effi-
cient production of mRBC at scale is now essentially a
biotechnological challenge that requires multidisciplinary
efforts. We have highlighted some of the key areas, break-
throughs and challenges (summarized in Table 2), in which
investment together with intensive research into further
optimization of culture systems and use of bioreactors at
scale are needed to make the clinical use of adult therapeu-
tic doses of mRBC become a reality. Focused research and
collaboration between academics, blood banks, commercial
entities and new spinouts, especially around the use of
RBC-based therapeutics, will no doubt help to drive the
development and efficiency of mRBC production under
GMP conditions into the clinic.
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